UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of June 2014

 

001-36203

(Commission File Number)

 

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

 

10 Bareket Street

Kiryat Matalon, P.O. Box 7537

Petach-Tikva 4951778, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

 

Form 20-F þ Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(7): ____

 

 
 

 

On June 2, 2014, Can-Fite BioPharma Ltd. (the “Company”) issued a press release announcing that the FDA has agreed with the Company’s study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

 
 

 

Exhibit Index

 

Exhibit No.   Description
     
99.1   Press Release, dated June 2, 2014

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Can-Fite BioPharma Ltd.
     
Date June 2, 2014 By: /s/ Motti Farbstein
    Motti Farbstein
    Chief Operating and Financial Officer